chloramphenicol has been researched along with Polycythemia Vera in 3 studies
Amphenicol: Chloramphenicol and its derivatives.
Polycythemia Vera: A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Potolsky, A | 1 |
| Creger, WP | 1 |
| Mathé, G | 1 |
| Amiel, JL | 1 |
| Schwarzenberg, L | 1 |
| Choay, J | 1 |
| Trolard, P | 1 |
| Schneider, M | 1 |
| Hayat, M | 1 |
| Schlumberger, JR | 1 |
| Jasmin, C | 1 |
| Rowley, JD | 1 |
| Blaisdell, RK | 1 |
| Jacobson, LO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment[NCT00065260] | Phase 2 | 54 participants (Actual) | Interventional | 2003-11-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with robust hematologic recovery with reticulocyte or platelet count ≥ 50,000/uL (NCT00065260)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| r-ATG /Cyclosporine | 9 |
| Alemtuzumab (Campath-1H) | 9 |
Percent of cumulative incidence of clonal evolution in participants to either paroxysmal nocturnal hemoglobinuria (PNH), myelodysplasia or acute leukemia. (NCT00065260)
Timeframe: 3 years
| Intervention | Percentage of Cumulative Incidence (Number) |
|---|---|
| r-ATG /Cyclosporine | 16 |
| Alemtuzumab (Campath-1H) | 5 |
Percentage of cumulative incidence of relapse of disease in participants (NCT00065260)
Timeframe: 3 year
| Intervention | percentage of cumulative incidence (Number) |
|---|---|
| r-ATG /Cyclosporine | 19 |
| Alemtuzumab (Campath-1H) | 9 |
Number of participants no longer meeting the criteria for severe aplastic anemia as measured by response to treatment at 6 months (NCT00065260)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| No Response | Partial Response | Complete Response | |
| Alemtuzumab (Campath-1H) | 17 | 9 | 0 |
| r-ATG /Cyclosporine | 18 | 9 | 0 |
Percentage of participants no longer meeting the criteria for severe aplastic anemia as measured by response to treatment (NCT00065260)
Timeframe: 3 months and 6 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 3 Months | 6 Months | |
| Alemtuzumab (Campath-1H) | 19 | 37 |
| r-ATG /Cyclosporine | 19 | 33 |
3 other studies available for chloramphenicol and Polycythemia Vera
| Article | Year |
|---|---|
Radiation and drug therapies, and leukemia.
Topics: Antineoplastic Agents; Benzene; Bone Marrow Diseases; Chloramphenicol; Cyclophosphamide; Dose-Respon | 1973 |
Bone marrow graft in man after conditioning by antilymphocytic serum.
Topics: Acute Disease; Adolescent; Adult; Agranulocytosis; Antilymphocyte Serum; Bone Marrow Transplantation | 1970 |
Chromosome studies in preleukemia. I. Aneuploidy of group C chromosomes in three patients.
Topics: Adult; Anemia; Anemia, Aplastic; Anemia, Sideroblastic; Chloramphenicol; Chromosome Aberrations; Chr | 1966 |